Petasites Study Group. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis

Allergy Clinic, Hochwangstrasse 3, CH-7302 Landquart, Switzerland.
BMJ Clinical Research (Impact Factor: 14.09). 02/2002; 324(7330):144-6. DOI: 10.1136/bmj.324.7330.144
Source: PubMed


To compare the efficacy and tolerability of butterbur (Petasites hybridus) with cetirizine in patients with seasonal allergic rhinitis (hay fever).
Randomised, double blind, parallel group comparison.
Four outpatient general medicine and allergy clinics in Switzerland and Germany.
131 patients were screened for seasonal allergic rhinitis and 125 patients were randomised (butterbur 61; cetirizine 64).
Butterbur (carbon dioxide extract tablets, ZE 339) one tablet, four times daily, or cetirizine, one tablet in the evening, both given for two consecutive weeks.
Scores on SF-36 questionnaire and clinical global impression scale.
Improvement in SF-36 score was similar in the two treatment groups for all items tested hierarchically. Butterbur and cetirizine were also similarly effective with regard to global improvement scores on the clinical global impression scale (median score 3 in both groups). Both treatments were well tolerated. In the cetirizine group, two thirds (8/12) of reported adverse events were associated with sedative effects (drowsiness and fatigue) despite the drug being considered a non-sedating antihistamine.
The effects of butterbur are similar to those of cetirizine in patients with seasonal allergic rhinitis when evaluated blindly by patients and doctors. Butterbur should be considered for treating seasonal allergic rhinitis when the sedative effects of antihistamines need to be avoided.

Download full-text


Available from: Andreas Schapowal, Mar 26, 2014
  • Source
    • "Butterbur has been extensively studied, especially related to its beneficial effects in allergic rhinitis. In a comparative, randomized study in 125 patients with SAR, both butterbur (butterbur-carbon dioxide extract tablets, Ze 339; 1 tablet, 4 times/day; n = 61) and cetirizine (1 tablet each evening; n = 64) were effective in improving SF-36 and global improvement scores [20]. However, sedative effects were observed in the cetirizine group. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. To determine the prevalence of herbal treatment of allergic rhinitis. Methods. In this prospective study, patients who were diagnosed with perennial allergic rhinitis were questioned about their use of natural products/herbal therapies for their symptoms. Results. In total, 230 patients were enrolled. Overall, 37.3% of the patients stated that they had used natural products/herbal therapies at least once. Women were more likely than men to use herbal supplements (38.3% versus 32.4%). Ten different types of herbal supplements were identified, with stinging nettle (Urtica dioicath), black elderberry (Sambucus nigra), and Spirulina being the most common (12.6%, 6.1%, and 5.7%, resp.). Conclusion. This study found a high prevalence of herbal treatment usage for the relief of allergic rhinitis symptoms in Turkey. The herbal products identified in this study and in the literature are discussed.
    11/2013; 2013(2):938751. DOI:10.1155/2013/938751
  • Source
    • "Besides Sinupret® and GeloMyrtol® can be used in acute and chronic bronchitis [6] and it could be shown that the efficacy of Sinupret® is superior to ambroxol and n-acetylcysteine [7–9]. It could be shown that Tesalin N® film tablets (containing a CO2-extract, Ze 339, of purple butterbur leaf (Petasites hybridus, Asteraceae), manufactured by Zeller Medical AG, Romanshorn, Switzerland) are as effective as fexofenadin and cetirizin in allergic rhinitis [10, 11]. A meta-analysis showed equivalent effectiveness when compared with non-sedative antihistamines [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Phytotherapeutic pharmaceuticals and herbal medicinal products with its roots in classical phytotherapeutic medicine have a well-established role in otolaryngological therapy, especially for diseases of the upper airways and acute and chronic infections. A thorough selection and application could mean huge benefit for the patient, in particular in cases with contraindications, chemo- and antibiotic resistance or patient request. Besides, it might spare other medications. Phytotherapeutic pharmaceuticals must fulfil the same criteria of quality, effectiveness and harmlessness of evidence-based medicine like chemical pharmaceuticals, although they are often prescribed due to its well established or traditional based use. This review focuses on phytotherapeutic therapies well established within the European Community for otolaryngologic disease patterns by referring to clinical studies or meta-analysis.
    Archives of Oto-Rhino-Laryngology 09/2011; 269(2):389-97. DOI:10.1007/s00405-011-1755-z · 1.55 Impact Factor
  • Source
    • "The PET extract was manufactured using liquid carbon dioxide with leaves of the cultivated Petasites variety PETZELL. The identical extract had already been used in clinical trials (Schapowal, 2002, 2004, 2005; Thomet et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The herbal Petasites hybridus (butterbur) extract (Ze 339, PET) is known to have leukotriene inhibiting properties, and therefore might inhibit allergic diseases. The effect of PET was investigated in ovalbumin (OVA) immunized BALB/c mice given intranasally together with antigen challenge in the murine model of allergic airway disease (asthma) with the analysis of the inflammatory and immune parameters in the lung. PET given with the antigen challenge inhibited the allergic response. PET inhibited airway hyperresponsiveness (AHR) and eosinophil recruitment into the bronchoalveolar lavage (BAL) fluid upon allergen challenge, but had no effect in the saline control mice. Eosinophil recruitment was further assessed in the lung by eosinophil peroxidase (EPO) activity at a concentration of 100 microg PET. Microscopic investigations revealed less inflammation, eosinophil recruitment and mucus hyperproduction in the lung with 100 microg PET. Diminution of AHR and inflammation was associated with reduced IL-4, IL-5 and RANTES production in the BAL fluid with 30 microg PET, while OVA specific IgE and eotaxin serum levels remained unchanged. PET, which has been reported to inhibit leukotriene activity, reduced allergic airway inflammation and AHR by inhibiting the production of the Th2 cytokines IL-4 and IL-5, and RANTES.
    Phytotherapy Research 10/2009; 24(5):680-5. DOI:10.1002/ptr.2972 · 2.66 Impact Factor
Show more